Ask AI

Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care

Gain global expert insights into PI3K/AKT/mTOR pathway inhibitor use in the management of HR+/HER2- metastatic breast cancer to optimize patient outcomes and minimize therapy-related toxicities, through commentaries, podcasts, Interactive Case Challenges, an Interactive Decision Support Tool, and a downloadable infographic.

Share

Program Content

Activities

PI3K/AKT Inhibitors in mBC
Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2025

PI3K/AKT-hämmare i metastatisk bröstcancer
Nya riktade behandlingar för metastatisk bröstcancer med PIK3CA/AKT1/PTEN-förändringar: Viktig evidens och insikter från klinisk praxis för att optimera patientvården
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 13, 2025

Inibidores de PI3K/AKT no mBC
Novas terapias direcionadas para o cancro da mama metastático com alterações em PIK3CA/AKT1/PTEN: evidências importantes e insights do mundo real para otimizar o tratamento de doentes
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 13, 2025

PI3K/AKT-Inhibitoren bei mbH (metastasierter Brustkrebs)
Neue zielgerichtete Therapien bei PIK3CA/AKT1/PTEN-verändertem metastasiertem Brustkrebs: Zentrale Evidenz und Erkenntnisse aus der Versorgungspraxis (Real-World-Daten) zur Optimierung der Patientenversorgung
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 15, 2025

Inibitori di PI3K/AKT nel mBC
Nuove terapie mirate per il carcinoma mammario metastatico con alterazioni dei geni PIK3CA/AKT1/PTEN: prove determinanti e approfondimenti dal mondo reale per ottimizzare la cura dei pazienti
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2025

Inhibiteurs de PI3K/AKT dans le cancer du sein métastatique
Nouveaux traitements ciblés pour le cancer du sein métastatique avec altération des gènes PIK3CA/AKT1/PTEN : des preuves essentielles et des informations concrètes pour optimiser les soins
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.